Comparative Pharmacology
Head-to-head clinical analysis: DIANEAL PD 1 W DEXTROSE 3 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 1 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIANEAL PD 1 W DEXTROSE 3 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 1 5 IN PLASTIC CONTAINER.
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER vs INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dianeal PD-1 with dextrose 3.5% is a peritoneal dialysis solution that uses dextrose as an osmotic agent to create an osmotic gradient across the peritoneal membrane, facilitating the removal of waste products (urea, creatinine) and excess fluid from the blood into the dialysate.
Inpersol-LC/LM with dextrose 1.5% is a peritoneal dialysis solution. The mechanism involves instillation into the peritoneal cavity, where dextrose creates an osmotic gradient that drives ultrafiltration of fluid and removal of uremic toxins (e.g., urea, creatinine) across the peritoneal membrane. The low calcium (LC) and low magnesium (LM) formulation helps prevent hypercalcemia and hypermagnesemia.
2-3 L intraperitoneally, dwell time 4-6 hours, 4-5 exchanges per day
Intraperitoneal administration: For continuous ambulatory peritoneal dialysis (CAPD), instill 2 liters of 1.5% dextrose solution into the peritoneal cavity via a permanent indwelling catheter. Exchange 4 times per day (every 6 hours) with a dwell time of 4-6 hours. For automated peritoneal dialysis (APD), typical regimen includes 2 liters per cycle with 4-5 cycles overnight and a daytime dwell.
None Documented
None Documented
Glucose: 1.5–2 hours (intraperitoneal administration leading to systemic absorption); clinical context: prolonged in renal impairment due to decreased clearance of metabolic products, but glucose itself is rapidly metabolized.
Not applicable via systemic absorption; glucose absorbed from dialysate exhibits a terminal half-life of 1.5–2 hours in plasma, reflecting rapid cellular uptake and metabolism.
Renal (virtually 100% of absorbed dextrose and metabolites); peritoneal dialysis removes glucose and metabolic byproducts, but significant elimination occurs via transperitoneal absorption into systemic circulation followed by renal excretion (in patients with residual renal function). In anuric patients, glucose is metabolized and eliminated as CO2 and water, with minimal direct excretion.
Renal: negligible; primarily eliminated via peritoneal dialysis (dialysate outflow). Biliary/fecal: <1%.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution